ESI-GROUP/FAW-VW
2.4.2024 08:01:33 CEST | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI) and FAW-Volkswagen (FAW-VW) TE have commemorated their strategic partnership with the signing of a Memorandum of Understanding (MoU) aimed at advancing intelligent simulation technology within the automotive industry. The ceremony, held at the FAW-VW R&D center in Changchun, Jilin Province, PRC, was officiated by Deng Guohui, Technical Development Director at FAW-VW, and Francis Griffiths, Executive Vice-President and Chief Revenue Officer at ESI Group.
The collaboration between ESI Group and FAW-VW TE aims to address the challenges posed by China's automotive safety regulations and drive industry innovation. Through this partnership, the two entities will aim to drive innovation and efficiency in intelligent simulation, and work towards establishing a localized automotive industry material database, thereby enhancing cooperation in advancing intelligent simulation technology across the industry. This collaborative effort is geared toward paving the way for a cleaner, safer, and more productive future.
Under the MoU, a material testing and intelligent simulation joint laboratory has been established, marking a significant step forward in intelligent simulation, innovation, and research within the automotive sector.
“With over 40 years of collaboration, ESI Group and VW Group have built strong ties, including a fruitful partnership with FAW-VW since 2007. This marks a significant milestone in our commitment to advancing virtual simulation technology in the automotive sector. Together with FAW-Volkswagen, we aim to drive innovation and efficiency in intelligent simulation, materials research and development,” declared Francis Griffiths, Executive Vice-President, Chief Revenue Officer at ESI Group.
"Today's milestone event celebrates not only two decades of fruitful collaboration but also embarks on a new era of innovation in automotive virtual simulation with ESI. This partnership signifies more than a formal agreement; it is a testament to our shared vision and commitment, aiming to pioneer intelligent simulation and materials research, setting new industry standards, and driving automotive safety and efficiency forward." declared Deng Guohui, Technical Development Director at FAW-VW.
During the ceremony, FAW-VW TE and ESI Group exchanged awards to honor their collaborative achievements in innovation. FAW-VW TE awarded ESI Group the prestigious "CAE Trusted Advisor" award, recognizing ESI's outstanding support in advancing virtual simulation technology in the automotive industry.
ESI Group reciprocated by presenting multiple global awards to FAW-VW's Technology Development team, including "Best Cooperation Partner" represented by Deng Guohui, Technical Development Director at FAW-VW and "Best Simulation Method Development Team" represented by Fu Xiaolong. Li Dapeng was also honored with the "'Virtual Performance Expert" award for their exceptional contributions. These accolades underscore the mutual respect, shared goals, and commitment of both companies to advancing automotive safety and efficiency through successful collaboration.
About ESI Group
ESI Group, a part of Keysight Technologies, provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise. Acting principally in automotive, land transportation, aerospace and defense, and heavy industry, ESI software enables engineers to simulate mechanical designs, smart manufacturing processes, and human-centric workflows to make better decisions earlier in the product lifecycle. Keysight is an S&P 500 company delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. For further information, go to: www.esi-group.com
Follow ESI LinkedIn | Facebook | Twitter | YouTube
About FAW-Volkswagen
Established on February 6, 1991, FAW-Volkswagen Automotive Co., Ltd. (hereinafter referred to as FAW-Volkswagen) is a large-sized passenger auto manufacturer jointly managed by First Automotive Group Corporation, Volkswagen AG, Audi AG and Volkswagen (China) Investment Co., Ltd. It is the domestic first modern passenger auto manufacturer constructed according to the economic scale.
Through the development of around 30 years, FAW-Volkswagen has had the capacity layout in Changchun in the Northeast, Chengdu in the Southwest, Foshan in South China, Qingdao in East China and Tianjin in North China. It boasts eight professional manufacturing factories, namely No. 1 Car Factory, No. 2 Car Factory, No. 3 Car Factory, No. 4 Car Factory, No. 5 Car Factory, No. 6 Car Factory, Business Division of Power Assembly, and Punching Center.
Add: No. 5 Anqing Road, Auto Industry Development District, Changchun Jilin Province, PRC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401600103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom